Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag FDA adds severe liver risk warning to Elevidys, restricts use to ambulatory boys age 4+ with Duchenne muscular dystrophy.

flag The FDA has updated Elevidys' label with a boxed warning for acute liver failure and serious liver injury, restricting its use to ambulatory boys aged 4 and older with Duchenne muscular dystrophy. flag The change follows three deaths, including two in non-ambulatory patients, prompting removal of that group from the approved indication. flag The therapy is now contraindicated in patients with certain DMD gene deletions, and strict monitoring and immunosuppressive regimens are required. flag Sarepta has paused shipments to non-ambulatory patients and will study a new immunosuppression approach to potentially restore access.

5 Articles

Further Reading